Published in final edited form as:

JPEN J Parenter Enteral Nutr. 2016 August ; 40(6): 860–868. doi:10.1177/0148607115572193.

A Safety and Dose-escalation Study of Intravenous Zinc Supplementation in Pediatric Critical Illness

Natalie Z. Cvijanovich, MD, FAAP¹, Janet C. King, PhD², Heidi R. Flori, MD, FAAP¹, Ginny Gildengorin, PhD², Alexander A. Vinks, PharmD, PhD^{3,5}, and Hector R. Wong, MD^{4,5}

¹Divisions of Critical Care at Children's Hospital and Research Center Oakland, Oakland, California

²Children's Hospital Oakland Research Institute, Oakland, California

³Division of Clinical Pharmacology, University of Cincinnati, Cincinnati, Ohio

⁴Division of Critical Care, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio

⁵Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio

Abstract

Background—Critically ill children have low plasma zinc (pZn), correlating with organ failure. Since Zn influences inflammation, immune function, and glucose control, Zn supplementation is a plausible therapeutic modality. We sought to determine a safe dose of IV Zn to restore pZn in critically ill children.

Methods—Stepwise dose-escalation study of IV Zn supplementation at a tertiary children's hospital. All children (<10 years) admitted to PICU with PRISM III score > 5 OR one new organ failure were eligible. After consent, patients were sequentially enrolled into 4 dosing groups: 1) No zinc, 2) Zn250: 250 µg/kg/day ZnSO₄, 3) Zn500: 500 µg/kg/day ZnSO₄, or 4) Zn750: 750 µg/kg/day ZnSO₄. ZnSO₄ was administered 3 times daily for 7 days. pZn was measured at baseline, end of first ZnSO₄ infusion, 1 hour post-infusion, and 7 hours post-infusion on Day 1, then daily trough Days 2–7. IL-6, CRP, and lymphocyte subsets were measured Days 1 and 3. Glucose was measured three times daily for 7 days.

Results—24 patients were enrolled. Baseline demographics were similar among groups. Baseline pZn was low in all patients (mean 41.8 µg/dL, standard deviation ± 16.0). pZn increased over the study period in supplemented groups; however, mean pZn in the Zn750 group exceeded 50th percentile. pZn was not associated with IL-6, CRP, or lymphocyte subsets among groups. Degree of hyperglycemia did not differ among groups. No patient had a study-related adverse event.

Conclusions—IV zinc supplementation at 500 µg/kg/day restores pZn to near 50th percentile and is well tolerated.

Keywords

Zinc; inflammation; lymphopenia; hyperglycemia; pediatrics; critical illness

Introduction

The association of low plasma zinc levels (pZn) with critical illness has become increasingly evident over the last several years, leading to a growing interest in investigating the potential therapeutic benefit of zinc supplementation^{1–10}. The biologic functions of zinc are varied, but in the setting of critical illness its involvement in the maintenance of intact immune function as well as its role in glucose homeostasis may be particularly relevant. Since decreased pZn is associated with critical illness, and in one study lower pZn was associated with increased numbers of organ failures and measures of inflammation¹¹, it is plausible that zinc supplementation may mitigate the effects of injury and illness and the associated dysregulation of the immune system and stress hyperglycemia that result in significant morbidity and mortality. Zinc has therefore been a component of multiple trials of immune enhancing formulas or “cocktails” in immunomodulatory treatments¹². To date, however, there has been no consistent demonstration of improvement in infection rates or mortality with this strategy.

Generally, supplemental zinc has been given orally in studies of children with diarrhea or pneumonia in developing countries, where pre-existing dietary zinc deficiency is common. A recent large, randomized, double-blind placebo controlled trial of oral zinc supplementation in 550 children 2–24 months old hospitalized with severe or very severe pneumonia showed no difference in time to recovery, though there was a trend toward more rapid recovery in the more severely ill group¹³. One of the reasons for this negative result may be that absorption via the oral route is impaired in the setting of critical illness¹⁴. Intravenous (IV) supplementation would eliminate this confounder; however, safety and dosing guidelines for IV zinc supplementation have not been established. We therefore completed a prospective phase I/II study of safety and pharmacokinetics of IV zinc supplementation in a population of critically ill children.

Materials and Methods

Setting and patients

This was a single center study performed in the pediatric intensive care unit (PICU) at Children’s Hospital & Research Center Oakland (CHRCO); [Clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT01062009) NCT01062009. CHRCO is a 179 bed free-standing children’s hospital, and the PICU is a 23 bed multidisciplinary unit that admits a broad spectrum of medical/surgical patients including patients who have undergone cardiac surgical procedures. Children admitted to the PICU from February 2009 to August 2012 were screened for study eligibility based on admission log and chart review.

Based on the pilot study that informed the current investigation¹¹, inclusion criteria were 1) age between 1 month and 10 years, 2) either unadjusted PRISM (Pediatric Risk of Mortality)

III score of greater than 5, as described by Pollock et al.¹⁵, OR at least 1 new organ failure as described by Proulx et al.¹⁶, and 3) anticipated PICU length of stay of > 3 days. Patients were excluded if 1) consent was not obtained, 2) they had known zinc deficiency (i.e., acrodermatitis enteropathica), 3) they had pre-existing bone marrow failure or a new or existing diagnosis of diabetes mellitus, 4) there were limitation of care orders in place or anticipated survival < 28 days, or 5) they had a clinical contraindication to zinc supplementation. After enrollment of the first three groups of patients, concern arose from review of existing literature that there may be potential harm with high dose zinc supplementation in the setting of neurologic injury^{17–19}, so an additional exclusion criterion of traumatic brain injury or new encephalopathy was added for enrollment in the high dose group. The Institutional Review Board at CHRCO approved the study, and all parents provided informed consent. Assent was waived due to the severity of illness of the eligible subjects. A Data Safety Monitoring Board was established that reviewed study results at the completion of enrollment of each study group.

Procedures

After consent was obtained, baseline demographic data were obtained. Study Day 0 was defined as the day of enrollment. In order to standardize administration times, zinc supplementation was started the following morning at 0800 (Study Day 1). Clinical data were recorded daily for 7 days. Because this was a safety and dose-finding pharmacokinetic study, patients were divided into four groups of six patients each, as determined by the pharmacokinetic modeling described below, with stepwise increase in zinc supplementation dose. The first (NoZn) group (6 patients) served as the control group and received no zinc supplementation, but serial pZn levels and all other study labs were performed as in the supplemented groups. Subsequent patients received zinc intravenously starting at 0800 on Day 1 through 2400 on Day 7, or until discharge if prior to 7 days, according the following progression: 1) the low dose (Zn250) group (6 patients) received 250 µg/kg/day of elemental zinc divided three times daily, 2) the medium dose (Zn500) group (6 patients) received 500 µg/kg/day of elemental zinc divided three times daily, and finally 3) the high dose (Zn750) group (6 patients) received 750 µg/kg/day of elemental zinc divided three times daily. Zinc was administered in the form of zinc sulfate (ZnSO₄), initially at a concentration of 100 µg/mL in 0.9% NaCl, prepared by the research pharmacy at CHRCO. Due to the potential relatively large volume that concentration resulted in for larger patients, the protocol was amended after the first three patients were enrolled, with the concentration being changed to 200 µg/mL ZnSO₄. All patients had central venous access and ZnSO₄ was administered centrally over one hour.

Progression to testing the next higher dose in the subsequent group of patients was based on two *a priori* criteria: 1) if pZn of the supplemented group was not restored to at least the 50th percentile in 4 of the 6 patients, and 2) the safety profile was acceptable, i.e., no increased fever without clinical cause, no decrease in plasma copper (given the inverse relationship between zinc and copper), and no other unexpected adverse event potentially attributable to zinc supplementation. Results of each group were summarized and presented to the DSMB prior to proceeding with enrollment of the subsequent 6 patients into the next higher dosing group.

Blood samples were obtained from indwelling central venous or arterial catheters and were aliquoted for processing as follows: 1) 0.5 mL into heparinized metal-free tubes on ice for analysis of zinc and copper levels (determined by atomic absorption, Children's Hospital Oakland Research Institute); 2) 0.5 mL into EDTA tube for Luminex interleukin-6 (IL-6) assays (Luminex, Austin, TX); 3) 2 mL for serum chemistries, albumin, alkaline phosphatase, and C-reactive protein (CRP); and 4) 1 mL into EDTA tube for complete blood count with differential and lymphocyte subsets. Whole blood glucose was measured at the bedside with Nova Statstrip Glucose Meter (Nova Biomedical, Waltham, MA). Urine was collected for determination of urinary zinc:creatinine ratio.

In order to assess the potential effect of zinc on glucose homeostasis, we developed a glucose homeostasis score (GHOS) to take into account the degree of hyperglycemia as well as the need for insulin over the course of the 7 day study period. This score is an ordinal scale ranging from 1 to 5, with a score of 1 indicating no hyperglycemia, and 5 indicating severe hyperglycemia despite insulin administration. The GHOS scale is based on increasing levels of serum glucose, which correspond to the American Diabetes Association guidelines for the diagnosis of diabetes and impaired glucose tolerance²⁰. In addition, the two highest glucose ranges in the GHOS scale have been correlated with increased mortality in critically ill children^{21,22}. Patients were assigned a daily GHOS based on the highest measured glucose of the day, plus an additional point if they were on insulin (Table 1).

Treatment guidelines were not standardized and were left at the discretion of the clinical care team. Specifically, patients received standard amounts of zinc from parenteral or enteral nutrition regardless of study group. Total zinc intake was recorded for each patient during the study period.

Data analysis

Data analysis was conducted using SAS Version 9.3. Basic descriptive analyses of all demographic, clinical, and laboratory data were conducted on each of the four groups in the study. Pearson correlations were used to assess the correlations of zinc levels with IL-6 and CRP levels. For examining the associations of zinc, CRP, and IL-6 levels and ratios with the number of organ failures Spearman's correlation and the Mann-Whitney test were used.

Differences between groups at baseline and in each follow-up were investigated for all demographic outcome variables using the appropriate analysis of variance model (ANOVA) and chi square analyses. When necessary, non-parametric Kruskal-Wallis or Mann-Whitney tests were applied. The major hypotheses of group differences and changes over time were evaluated using general linear models for longitudinal data. The use of longitudinal models enabled us to account for within-patient correlations that were introduced in the data by the repeated measures across the study time-points. Models also adjusted for baseline differences when necessary. If significant differences were found between the groups, Tukey's method of multiple comparisons was used. A significance level of 0.05 was used for all statistical tests.

Pharmacokinetic analysis

A zinc pharmacokinetic profile was determined for each individual patient at the start of treatment on Day 1. Based on results of our previously published pilot study of pZn in 20 critically ill patients, a sample size of six patients in each group was determined to be adequate for pharmacokinetic parameter estimation. Samples for pharmacokinetic analysis were drawn according to a sparse D-optimal sampling strategy²³. In addition, to allow estimation of zinc exposure during therapy six pre-dose (trough) samples were drawn at 24, 48, 72, 84, 96 and 106 hours into therapy. Plasma concentration-time data were explored graphically and by compartmental analysis with the software package MW/Pharm (Version 3.6, Mediware, Groningen, the Netherlands)^{24,25}. Pharmacokinetic (PK) analysis was performed using a Bayesian PK model-based approach with a zinc population model adapted from the literature using allometric scaling^{26–28}. Post hoc Bayesian parameter estimates were generated for zinc total body clearance, volume of distribution and half-life. The PK model was also used to evaluate predicted zinc concentration-time profiles as part of the dose escalation study.

Results

During the study period, 24 patients were enrolled, with 6 patients enrolled in each group sequentially. The baseline demographic characteristics are shown in Table 2. The underlying diagnoses were varied, as expected, and included sepsis in 4, pneumonia (viral or bacterial) in 8, trauma (including traumatic brain injury) in 5, repair of congenital heart disease in 2, intestinal volvulus in 2, and encephalitis, intracranial hemorrhage, and hydrocarbon inhalation each in one child. All patients completed the study, and no patients died during the study. There were no differences in baseline demographics among the four groups of patients.

Zinc

All patients had low pZn on Day 1 of ICU admission ($41.8 \mu\text{g/dL} \pm 16.0$) (mean $\pm$ SD) compared with normal reference ranges. The 50th percentile range of normal pZn in children < 10 years old is 75–80 $\mu\text{g/dL}$ and the 2.5th percentile is 56–57 $\mu\text{g/dL}$. There was no difference found in baseline pZn among groups ($p=0.44$). Whereas the NoZn (control) group showed no increase in pZn over the 7 day study period ($p=0.54$), pZn increased significantly from Day 1 to Day 7 in all three zinc supplemented groups (Zn250, $p=0.01$; Zn500, $p=0.03$; Zn750, $p<0.0001$ comparing Day 1 to Day 7). Furthermore, among the three zinc supplemented groups, pZn increased more rapidly as the dose increased (Figure 1A). In the Zn750 group, pZn levels reached the 50th percentile by Day 7 of supplementation (mean $93.3 \mu\text{g/dL}$; $\text{SD} \pm 8.75$). Plasma copper levels increased slightly with time in all three zinc supplemented groups, $p=0.03$ (Figure 1B), but remained within normal limits.

Zinc and intermediate outcomes

Over the seven day period of zinc supplementation, PELOD²⁹ scores decreased in all groups, but there was no difference in scores among groups. All patients had at least one organ failure on the day of enrollment, and organ failure tended to resolve by Day 7, though

because of the small number of patients in each group, statistical significance could not be tested.

The correlations between pZn and IL-6 or CRP on Day 1 were not significant (Zn and IL-6, $r = -0.39$, $p = 0.06$; Zn and CRP, $r = -0.32$, $p = 0.14$). There was no difference in interleukin-6 (IL-6) on Day 1 across dosing groups, nor was there a significant change in IL-6 with time among groups. The NoZn group had significantly lower Day 1 C-reactive protein (CRP) levels than the Zn750 group ($p=0.02$), but there was no significant difference in the change in CRP over all time points ($p=0.30$) (see Table 3). There was no difference in urinary excretion of zinc between or among groups over all time points, $p=0.12$ (data not shown). There was also no difference in lymphocyte numbers, distribution of lymphocyte subsets on Day 1 or Day 3 of PICU admission, or change in lymphocyte subsets over time among the four groups (Table 3).

The Zn750 group tended to have lower median GHOS scores, but there was no difference in median GHOS between the controls and the zinc supplemented groups at all time points ($p=0.08$) (Figure 2).

Zinc dosing

Plasma zinc pharmacokinetics were calculated for each patient based on the Day 1 profile as well as the subsequent daily trough levels. A sample graph from a patient in each supplemented group is provided for illustration (Figure 3). In aggregate, mean clearance was 5.77 ± 2.57 mL/hr/kg, volume of distribution was 1.39 ± 0.46 L/kg, and $T_{1/2}$ (half life) was 181.36 ± 56.29 hours. Based on pharmacokinetic modeling, the 500 $\mu\text{g/kg/day}$ IV zinc supplementation dose nearly restored levels to within the normal range, without inducing prolonged periods of pZn above normal.

Safety

The zinc infusion appeared to be well tolerated by all children. Early in the study it was the subjective impression of the nursing staff that the infusion may cause some degree of phlebitis when infused peripherally, so subsequent infusions were given centrally. All children in the study had central venous access. Potential safety concerns determined prior to the study included fever, anemia, and decreased copper levels. Given the inclusion criteria of critical illness as determined by PRISM score and organ failure, the study population was expected to have some degree of fever and anemia as a function of illness severity. There was no significant difference in the onset of new fever among study groups ($p=0.24$). Copper levels were not affected by zinc supplementation (Figure 1B). There were no adverse events related to the study. One infant with respiratory syncytial virus (RSV) sepsis developed refractory hypoxemia and required cannulation for ECMO (extracorporeal membrane oxygenation) on study Day 6, but this event was reviewed by the DSMB and determined to be unrelated to the study. No children died, and there was no negative effect attributable to zinc supplementation.

Discussion

This is the first study of intravenous (IV) zinc supplementation in critically ill children. Consistent with previous studies of zinc in critically ill children^{11,30}, pZn was low at baseline and increased over the 7-day study period. Importantly, IV zinc was well tolerated in all dosing groups. All of the children in the 750 µg/kg/day group achieved normal plasma zinc levels, but four of the six children in that group had supra-therapeutic levels of plasma zinc (>120 µg/dL). There did not appear to be toxicity associated with this, but given the small number of patients in the group we cannot conclude that 750 µg/kg/day is safe. Although we do not yet have evidence of a beneficial physiologic effect of any of the doses in this pilot/safety study, based on the pharmacologic data demonstrating restoration toward normal without exceeding the upper range of normal, we concluded that 500 mcg/kg/day is a well-tolerated dose of IV zinc supplementation in critically ill children, and is a reasonable starting point for a randomized, controlled, multicenter trial to evaluate the safety, efficacy, and clinical benefit of this intervention.

In recent years there has been a paradigm shift in the concept of nutrition as a therapeutic modality, specifically the use of micronutrients as “pharmaconutrients” to positively impact outcomes in critical illness. There has been growing interest in administration of micronutrients for anti-oxidant effect, anti-inflammatory properties, and immunomodulation^{2–5,7–10,31–39}. Some common components of these “cocktails” have included glutamine, arginine, omega-3 fatty acids, selenium, and zinc. Unfortunately, studies have often combined several of these micronutrients in one patient population. This method runs the risk of masking a potential beneficial, or harmful, effect of a single component of the cocktail. In a recently published large, randomized study of supplementation of critically ill children with glutamine, selenium, zinc and metoclopramide⁹, no benefit of the combination of pharmaconutrients was demonstrated, though in a subgroup of immunocompromised patients there was a lower incidence of healthcare associated infection. Since then, a large trial of glutamine and anti-oxidant supplementation in critically ill adults showed an *increase* in mortality among the glutamine-supplemented group, and no improvement in outcomes among patients supplemented with an anti-oxidant combination comprised of selenium, zinc, beta carotene, Vitamin E and Vitamin C³⁵. Thus it is imperative to evaluate micronutrients individually to the extent possible in order to determine effects specific to that micronutrient.

The association of decreased plasma zinc levels with acute illness has been demonstrated in multiple studies^{11,40–43}. The exact mechanism by which this occurs, and the benefit or detriment of this response is not clear. In a study of genomic responses of children with SIRS/sepsis, decreased plasma zinc levels were associated with non-survival in the setting of septic shock⁴⁴. A subsequent pilot study of 20 critically ill children presenting with a wide range of diagnoses demonstrated that decreased plasma Zn levels correlated with degree of organ failure¹¹. It is important to note that these decreased plasma Zn levels are not a true zinc deficiency, but are rather, at least in part, a reflection of the body’s response to illness or injury. It has been shown that in acute illness, Zn is redistributed from the serum to other tissues⁴⁵. One of the most important mechanisms for this redistribution is induction of hepatic metallothioneins, which are cysteine-rich intracellular metal binding proteins

important in the homeostasis of essential metals and participants in the acute inflammatory response. Levels of hepatic metallothioneins increase rapidly in response to cytokine release associated with inflammation or injury, quickly sequestering plasma zinc into the liver for the synthesis of acute phase proteins essential to the stress response^{45,46}. Furthermore, this stress response results in acutely increased urinary Zn excretion^{40,47–49}, decreasing total body zinc stores. A temporary decrease in plasma Zn may be beneficial in limiting the cytokine response during inflammation⁴⁵. Since zinc is a trace element required by all organisms, including bacteria and fungi, one can postulate that low plasma zinc levels might in part be a protective host response, limiting availability of zinc to bacteria, analogous to the acute drop in iron levels in the setting of sepsis^{50,51}. There is, however, no evidence to support this theory, and in fact a recent study by Eijkelkamp et al.⁵² described a mechanism for a potential toxic effect of extracellular zinc on *S. pneumoniae*. It is unlikely, therefore, that zinc supplementation would be harmful, but this question clearly requires further investigation.

This study was a pilot/safety study and as such was not powered to evaluate efficacy of IV zinc supplementation, but outcome variables reflected potential areas of benefit. Zinc is known to be required for normal function of the immune system, has anti-inflammatory properties, and is required for insulin function and glucose homeostasis. It has been well established that pZn is low in the setting of critical illness^{9,11,41}, and the degree of relative hypozincemia correlates with organ failure^{9,11}. Zinc supplementation has the potential to positively impact morbidity and perhaps mortality associated with critical illness, but until now there have not been established guidelines for dosing, pharmacokinetics or safety profile to inform a large-scale, randomized, placebo-controlled efficacy trial of IV zinc supplementation. We chose to evaluate markers of inflammation (IL-6 and CRP), immunodeficiency/immunoparalysis (lymphocyte subsets), and glucose homeostasis in order to model such a large scale trial, but without the intent to determine efficacy based on these parameters.

Although enteral zinc supplementation has been studied extensively both in the developing world^{7,8,53–55}, where dietary zinc deficiency is relatively common, as well as in some populations of critically ill patients^{3,4,6,9,35,56,57}, there have been very few studies of parenteral zinc supplementation, with the majority having been done in populations known to have increased zinc losses, such as burn patients^{3,4,58,59}, and none in pediatrics. Parenteral zinc is thought to be safe and is routinely used in parenteral nutrition preparations. There are no reports of toxicity from IV zinc in physiologic doses, and doses as high as 900 mcg/kg/day have been well tolerated⁶⁰. Two case reports of accidental significant parenteral zinc overdose describe fever and anemia^{61,62}. In this study we had no evidence of toxicity among the supplemented patients.

There was concern that copper levels would be affected by zinc supplementation. Although the most significant interaction between zinc and copper administration occurs when these trace elements are given enterally, there is some evidence that there may be post-absorptive interactions between copper and zinc with regard to modulation of metallothionein expression, with concomitant alteration in metal concentrations⁶³. With this potential concern in mind, since copper levels were included in the measurement of trace element

levels and did not require additional blood sampling, we elected to analyze them to ensure that there was no evidence of a significant interaction. However, we found no decrease in plasma copper with zinc supplementation.

Limitations of the study include the small sample size in each group, with multiple comparisons. The study population was quite varied in age and diagnosis, and it is possible that zinc supplementation would have differing effects in more homogeneous diagnostic subgroups of patients. However, for the purposes of this phase I/II study, and based on the pilot study of zinc homeostasis in critically ill children, the authors felt that this diversity provides generalizability for future studies. Secondly, measurement of plasma zinc does not reflect the total body zinc status of a patient, and therefore a patient with low pZn may not have true zinc deficiency. However, since previous work has shown a correlation between pZn and organ failure¹¹, and furthermore there is currently no “gold standard” measurement of zinc status, in order to minimize phlebotomy and obtain pharmacokinetic and pharmacodynamic measurements we elected to use pZn as our outcome measure. Finally, the compensatory anti-inflammatory response syndrome (CARS) associated with critical illness and initial systemic inflammatory response is generally recognized to occur 7–10 days after the initial insult, so measurement of inflammatory markers and lymphocyte subsets on Day 3 were likely premature. However, given the small number of patients in each group and the short average length of stay of PICU patients in general, we felt that waiting until Day 7 of supplementation would result in loss of data points.

Conclusion

Low plasma zinc levels are prevalent among critically ill children and are associated with the degree of organ failure. Intravenous zinc supplementation is a biologically plausible therapeutic modality, but until now safety and appropriate dosing has not been established. Based on this dose-escalation study, IV zinc supplementation is well-tolerated, and a dose of 500 µg/kg/day restores plasma zinc levels to near the 50th percentile of normal values without exceeding normal concentrations. A multi-center, randomized, controlled trial of IV zinc supplementation to study its effect on inflammation, immunity, and glucose homeostasis is warranted.

Acknowledgments

This work was supported in part by an intramural grant from Children’s Hospital and Research Center Oakland and by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1 RR024131. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

References

1. Bao B, Prasad AS, Beck FWJ, et al. Zinc supplementation decreases oxidative stress, incidence of infection, and generation of inflammatory cytokines in sickle cell disease patients. *Translational Research*. 2008; 152(2):67–80. [PubMed: 18674741]
2. Berger MM. Antioxidant micronutrients in major trauma and burns: evidence and practice. *Nutr Clin Pract*. Oct; 2006 21(5):438–449. [PubMed: 16998143]

3. Berger MM, Baines M, Raffoul W, et al. Trace element supplementation after major burns modulates antioxidant status and clinical course by way of increased tissue trace element concentrations. *Am J Clin Nutr.* May; 2007 85(5):1293–1300. [PubMed: 17490965]
4. Berger MM, Baines M, Raffoul W, et al. Trace element supplementation after major burns modulates antioxidant status and clinical course by way of increased tissue trace element concentrations. *Am J Clin Nutr.* May 1; 2007 85(5):1293–1300. 2007. [PubMed: 17490965]
5. Berger MM, Shenkin A. Update on clinical micronutrient supplementation studies in the critically ill. *Curr Opin Clin Nutr Metab Care.* Nov; 2006 9(6):711–716. [PubMed: 17053424]
6. Berger MM, Spertini F, Shenkin A, et al. Clinical, immune and metabolic effects of trace element supplements in burns: a double-blind placebo-controlled trial. *Clin Nutr.* Apr; 1996 15(2):94–96. [PubMed: 16844008]
7. Bhutta ZA, Bird SM, Black RE, et al. Therapeutic effects of oral zinc in acute and persistent diarrhea in children in developing countries: pooled analysis of randomized controlled trials. *Am J Clin Nutr.* Dec; 2000 72(6):1516–1522. [PubMed: 11101480]
8. Brooks WA, Yunus M, Santosham M, et al. Zinc for severe pneumonia in very young children: double-blind placebo-controlled trial. *Lancet.* May 22; 2004 363(9422):1683–1688. [PubMed: 15158629]
9. Carcillo JA, Dean JM, Holubkov R, et al. The randomized comparative pediatric critical illness stress-induced immune suppression (CRISIS) prevention trial. *Pediatr Crit Care Med.* Mar; 2012 13(2):165–173. [PubMed: 22079954]
10. Failla ML. Trace elements and host defense: recent advances and continuing challenges. *J Nutr.* May; 2003 133(5 Suppl 1):1443S–1447S. [PubMed: 12730439]
11. Cvijanovich NZ, King JC, Flori HR, Gildengorin G, Wong HR. Zinc homeostasis in pediatric critical illness. *Pediatr Crit Care Med.* Jan; 2009 10(1):29–34. [PubMed: 19057435]
12. Heyland DK, Jones N, Cvijanovich NZ, Wong H. Zinc supplementation in critically ill patients: a key pharmacconutrient? *JPEN J Parenter Enteral Nutr.* Sep-Oct; 2008 32(5):509–519. [PubMed: 18669902]
13. Wadhwa N, Chandran A, Aneja S, et al. Efficacy of zinc given as an adjunct in the treatment of severe and very severe pneumonia in hospitalized children 2–24 mo of age: a randomized, double-blind, placebo-controlled trial. *Am J Clin Nutr.* Jun; 2013 97(6):1387–1394. [PubMed: 23636236]
14. Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. *Critical care clinics.* Apr; 2006 22(2):255–271, vi. [PubMed: 16677999]
15. Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated Pediatric Risk of Mortality score. *Crit Care Med.* May; 1996 24(5):743–752. [PubMed: 8706448]
16. Proulx F, Gauthier M, Nadeau D, Lacroix J, Farrell CA. Timing and predictors of death in pediatric patients with multiple organ system failure. *Crit Care Med.* Jun; 1994 22(6):1025–1031. [PubMed: 8205810]
17. Aquilani R, Sessarego P, Iadarola P, Barbieri A, Boschi F. Nutrition for brain recovery after ischemic stroke: an added value to rehabilitation. *Nutr Clin Pract.* Jun; 2011 26(3):339–345. [PubMed: 21586419]
18. Bitanirwe BK, Cunningham MG. Zinc: the brain's dark horse. *Synapse.* Nov; 2009 63(11):1029–1049. [PubMed: 19623531]
19. Shuttleworth CW, Weiss JH. Zinc: new clues to diverse roles in brain ischemia. *Trends in pharmacological sciences.* Aug; 2011 32(8):480–486. [PubMed: 21621864]
20. Silverstein J, Klingensmith G, Copeland K, et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. *Diabetes care.* Jan; 2005 28(1):186–212. [PubMed: 15616254]
21. Faustino EV, Apkon M. Persistent hyperglycemia in critically ill children. *J Pediatr.* Jan; 2005 146(1):30–34. [PubMed: 15644818]
22. Wintergerst KA, Buckingham B, Gandrud L, Wong BJ, Kache S, Wilson DM. Association of hypoglycemia, hyperglycemia, and glucose variability with morbidity and death in the pediatric intensive care unit. *Pediatrics.* Jul; 2006 118(1):173–179. [PubMed: 16818563]
23. D'Argenio DZ. Optimal sampling times for pharmacokinetic experiments. *J Pharmacokinet Biopharm.* 1981; 9(6):739–756. [PubMed: 7341758]

24. Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. *Comput Biol Med.* 1992; 22(3):155–163. [PubMed: 1617949]
25. Jelliffe RW, Schumitzky A, Bayard D, et al. Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals. *Clin Pharmacokinet.* Jan; 1998 34(1):57–77. [PubMed: 9474473]
26. Feillet-Coudray C, Meunier N, Rambeau M, et al. Long-term moderate zinc supplementation increases exchangeable zinc pool masses in late-middle-aged men: the Zenith Study. *Am J Clin Nutr.* Jul; 2005 82(1):103–110. [PubMed: 16002807]
27. Lowe NM, Shames DM, Woodhouse LR, et al. A compartmental model of zinc metabolism in healthy women using oral and intravenous stable isotope tracers. *Am J Clin Nutr.* Jun; 1997 65(6): 1810–1819. [PubMed: 9174477]
28. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. *Drug metabolism and pharmacokinetics.* 2009; 24(1):25–36. [PubMed: 19252334]
29. Leterurtre S, Duhamel A, Grandbastien B, Lacroix J, Leclerc F. Paediatric logistic organ dysfunction (PELOD) score. *Lancet.* Mar 18.2006 367(9514):897. author reply 900–892.
30. Heidemann SM, Holubkov R, Meert KL, et al. Baseline serum concentrations of zinc, selenium, and prolactin in critically ill children. *Pediatric critical care medicine: a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.* May; 2013 14(4):e202–206.
31. Berger MM, Reymond MJ, Shenkin A, et al. Influence of selenium supplements on the post-traumatic alterations of the thyroid axis: a placebo-controlled trial. *Intensive Care Med.* Jan; 2001 27(1):91–100. [PubMed: 11280679]
32. Darlow BA, Austin NC. Selenium supplementation to prevent short-term morbidity in preterm neonates. *Cochrane Database Syst Rev.* 2003; 4:CD003312.
33. Dubick MA, Williams C, Elgjo GI, Kramer GC. High-dose vitamin C infusion reduces fluid requirements in the resuscitation of burn-injured sheep. *Shock.* Aug; 2005 24(2):139–144. [PubMed: 16044084]
34. Hardy G, Hardy I, Manzanares W. Selenium supplementation in the critically ill. *Nutr Clin Pract.* Feb; 27(1):21–33.
35. Heyland D, Muscedere J, Wischmeyer PE, et al. A randomized trial of glutamine and antioxidants in critically ill patients. *N Engl J Med.* Apr 18; 2013 368(16):1489–1497. [PubMed: 23594003]
36. Heyland DK, Dhaliwal R, Day AG, et al. REDucing Deaths due to OXidative Stress (The REDOXS Study): Rationale and study design for a randomized trial of glutamine and antioxidant supplementation in critically-ill patients. *Proc Nutr Soc.* Aug; 2006 65(3):250–263. [PubMed: 16923310]
37. Manzanares W, Hardy G. Selenium supplementation in the critically ill: posology and pharmacokinetics. *Curr Opin Clin Nutr Metab Care.* May; 2009 12(3):273–280. [PubMed: 19333120]
38. Pontes-Arruda A, Demichele S, Seth A, Singer P. The use of an inflammation-modulating diet in patients with acute lung injury or acute respiratory distress syndrome: a meta-analysis of outcome data. *JPEN J Parenter Enteral Nutr.* Nov-Dec;2008 32(6):596–605. [PubMed: 18974237]
39. Valenta J, Brodská H, Drabek T, Hendl J, Kazda A. High-dose selenium substitution in sepsis: a prospective randomized clinical trial. *Intensive Care Med.* May; 37(5):808–815. [PubMed: 21347869]
40. Boosalis MG, Solem LD, McCall JT, Ahrenholz DH, McClain CJ. Serum zinc response in thermal injury. *J Am Coll Nutr.* Feb; 1988 7(1):69–76. [PubMed: 3278040]
41. Duggan C, MacLeod WB, Krebs NF, et al. Plasma zinc concentrations are depressed during the acute phase response in children with falciparum malaria. *J Nutr.* Apr; 2005 135(4):802–807. [PubMed: 15795438]
42. Heidemann SM, Holubkov R, Meert KL, et al. Baseline serum concentrations of zinc, selenium, and prolactin in critically ill children. *Pediatr Crit Care Med.* May; 14(4):e202–206.

43. Uckan D, Cetin M, Dincer N, Kalkan G, Tuncer M, Tezcan I. Serum zinc and alkaline phosphatase values in pediatric bone marrow transplantation patients. *Pediatr Hematol Oncol.* Jun; 2003 20(4): 265–271. [PubMed: 12746158]
44. Wong HR, Shanley TP, Sakthivel B, et al. Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome. *Physiol Genomics.* Jul 18; 2007 30(2):146–155. [PubMed: 17374846]
45. Liuzzi JP, Lichten LA, Rivera S, et al. Interleukin-6 regulates the zinc transporter Zip14 in liver and contributes to the hypozincemia of the acute-phase response. *Proc Natl Acad Sci U S A.* May 10; 2005 102(19):6843–6848. [PubMed: 15863613]
46. King JC. Zinc: an essential but elusive nutrient. *Am J Clin Nutr.* Aug; 2011 94(2):679S–684S. [PubMed: 21715515]
47. Boosalis MG, Solem LD, Cerra FB, et al. Increased urinary zinc excretion after thermal injury. *J Lab Clin Med.* Dec; 1991 118(6):538–545. [PubMed: 1744502]
48. Klaiman AP, Victory W, Kluger MJ, Vander AJ. Urinary excretion of zinc and iron following acute injection of dead bacteria in dog. *Proc Soc Exp Biol Med.* Jun; 1981 167(2):165–171. [PubMed: 7232422]
49. Victory W, Levenson R, Vander AJ. Effect of glucagon on zinc excretion in anesthetized dogs. *Am J Physiol.* Apr; 1981 240(4):F299–305. [PubMed: 7223888]
50. Weinberg ED. Iron loading and disease surveillance. *Emerging infectious diseases.* May-Jun; 1999 5(3):346–352. [PubMed: 10341171]
51. Rech M, To L, Tovbin A, Smoot T, Mlynarek M. Heavy metal in the intensive care unit: a review of current literature on trace element supplementation in critically ill patients. *Nutr Clin Pract.* Feb; 2014 29(1):78–89. [PubMed: 24336443]
52. Eijkelkamp BA, Morey JR, Ween MP, et al. Extracellular zinc competitively inhibits manganese uptake and compromises oxidative stress management in *Streptococcus pneumoniae*. *PloS one.* 2014; 9(2):e89427. [PubMed: 24558498]
53. Bhutta ZA, Black RE, Brown KH, et al. Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials. Zinc Investigators' Collaborative Group. *J Pediatr.* Dec; 1999 135(6):689–697. [PubMed: 10586170]
54. Ruel MT, Rivera JA, Santizo MC, Lonnerdal B, Brown KH. Impact of zinc supplementation on morbidity from diarrhea and respiratory infections among rural Guatemalan children. *Pediatrics.* Jun; 1997 99(6):808–813. [PubMed: 9164774]
55. Sazawal S, Black RE, Ramsan M, et al. Effect of zinc supplementation on mortality in children aged 1–48 months: a community-based randomised placebo-controlled trial. *Lancet.* Mar 17; 2007 369(9565):927–934. [PubMed: 17368154]
56. Heyland, DK. Supplemental Antioxidant Nutrients: Parenteral Selenium. Clinical Practice Guidelines. 2009. http://www.criticalcarenutrition.com/index.php?option=com_content&task=view&id=17&Itemid=40
57. Pontes-Arruda A, Martins LF, de Lima SM, et al. Enteral nutrition with eicosapentaenoic acid, gamma-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT study. *Crit Care.* 15(3):R144. [PubMed: 21658240]
58. Berger MM, Soguel L, Shenkin A, et al. Influence of early antioxidant supplements on clinical evolution and organ function in critically ill cardiac surgery, major trauma, and subarachnoid hemorrhage patients. *Crit Care.* 2008; 12(4):R101. [PubMed: 18687132]
59. Young B, Ott L, Kasarskis E, et al. Zinc supplementation is associated with improved neurologic recovery rate and visceral protein levels of patients with severe closed head injury. *Journal of neurotrauma.* Jan; 1996 13(1):25–34. [PubMed: 8714860]
60. Lowe NM, Woodhouse LR, Sutherland B, et al. Kinetic parameters and plasma zinc concentration correlate well with net loss and gain of zinc from men. *J Nutr.* Sep; 2004 134(9):2178–2181. [PubMed: 15333701]
61. Brocks A, Reid H, Glazer G. Acute intravenous zinc poisoning. *British medical journal.* May 28; 1977 1(6073):1390–1391. [PubMed: 405076]

62. Gallery ED, Blomfield J, Dixon SR. Acute zinc toxicity in haemodialysis. British medical journal. Nov 11; 1972 4(5836):331–333. [PubMed: 4637513]
63. Irato P, Albergoni V. Interaction between copper and zinc in metal accumulation in rats with particular reference to the synthesis of induced-metallothionein. Chemico-biological interactions. Aug 15; 2005 155(3):155–164. [PubMed: 16083871]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Clinical Relevancy Statement

Zinc status influences multiple aspects of the host response to stress from illness or trauma, and low plasma zinc concentrations are associated with critical illness. Zinc supplementation presents a potential therapeutic intervention to improve morbidity and mortality associated with critical illness. This study is the first to assess the safety and appropriate dosing of IV zinc in critically ill children. The results will inform a multicenter randomized clinical trial of zinc supplementation to assess its efficacy in improving immune function and glycemic control.

Figure 1.

Mean plasma Zn and Cu concentrations over time. **A.** Plasma zinc (pZn) concentration by group. Single horizontal line represents 50th percentile (75 µg/dL) Day 1 to Day 7 change: *No Zn, $p=0.54$; **Zn250, $p=0.01$; #Zn500, $p=0.03$; ##Zn750, $p<0.001$ **B.** Plasma copper (pCu) concentration by group. Single horizontal line represents 50th percentile (65 µg/dL). Day 1 to Day 7 change * $p=0.03$; **NS=not significant

Figure 2. Median daily glucose homeostasis score (GHOS) by study group. Higher number indicates greater degree of hyperglycemia. *p=0.08 for change in score among groups

Figure 3. Pharmacokinetic profiles of a representative patient from each supplemented study group. Dashed horizontal lines represent 2.5th, 50th, and 97.5th percentile [pZn]. Open circles represent specific time points of measurement. **A.** Zn250 patient; **B.** Zn 500 patient; **C.** Zn750 patient. **Note:** Scale in **C** has been widened to optimize graph

Table 1

Glucose homeostasis score (GHOS)

Maximum daily glucose (mg/dL)	Points*
<100	1
100–125	2
126–140	3
>140	4

*
Insulin infusion adds 1 point to the maximum score

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2

Patient characteristics

Characteristic	NoZn (N=6)	Zn250 (N=6)	Zn500 (N=6)	Zn750 (N=6)	p value
Age (years; median, IQR)	1.5 (0.6–4.8)	1.8 (0.8–2.8)	5.3 (1.9–6.4)	2.8 (0.8–5.2)	0.59
Gender					0.72
Male	33% (2)	50% (3)	33% (2)	50% (3)	
Female	67% (4)	50% (3)	67% (4)	50% (3)	
Severity of illness					
PRISM III (median, IQR)	12 (5–17)	8 (3–16)	12 (6–19)	9 (7–10)	0.92
PIM (median, IQR)	3.4 (1.6–17.1)	6.0 (4.2–7.2)	7.0 (4.0–23.0)	5.2 (2.8–7.8)	0.47
PELOD (median)	11 (4–11)	11 (4–19)	20 (13–21)	21 (14–21)	0.23
No of pts with 2 organs failed	50% (3)	50% (3)	67% (4)	50% (3)	0.88
Length of stay (days; median, IQR)					
PICU	8 (8–11)	8 (5.75–18.5)	18.5 (10.8–26.25)	10.5 (8.5–11.75)	0.61
Hospital	10 (8.25–16.25)	12 (8.75–28.75)	25.5 (15.8–33.75)	16 (13.5–20.75)	0.47

Table 3

Lymphocyte subsets and inflammatory markers

Lymphocytes (mean ± SD)	No Zn			Zn250			Zn500			Zn750			p-value
	Day 1	Day 3	Day 1	Day 1	Day 3	Day 1	Day 1	Day 3	Day 1	Day 1	Day 3	Day 3	
Total T %	65.8 (7.2)	67.8 (13.3)	60.0 (9.3)	63.2 (17.0)	62.7 (11.1)	67.7 (12.1)	61.0 (15.6)	66.8 (18.1)	NS *				
CD4 %	42.4 (6.8)	43.8 (16.9)	35.0 (5.8)	40.0 (16.3)	39.5 (12.1)	44.5 (11.8)	41.8 (15.0)	48.8 (18.8)	NS				
CD8 %	22.0 (7.6)	18.8 (4.4)	22.2 (11.0)	21.0 (10.1)	20.5 (4.9)	21.2 (5.2)	17.2 (3.6)	17.2 (6.3)	NS				
CD19 %	29.4 (6.5)	23.3 (6.1)	35.2 (10.0)	31.2 (14.8)	33.7 (9.9)	28.8 (12.4)	34.6 (12.6)	28.3 (15.5)	NS				
NK %	3.4 (2.3)	7.3 (7.8)	3.4 (2.4)	3.3 (2.4)	2.2 (2.0)	1.8 (0.8)	3.8 (3.7)	3.8 (3.7)	NS				
CD4/CD8 ratio	2.12 (0.85)	2.7 (1.5)	2.1 (1.4)	2.5 (2.1)	2.1 (0.9)	2.2 (0.9)	2.5 (1.1)	3.2 (1.7)	NS				
Inflammatory markers (median, IQR)													
IL-6 (pg/mL)	50.5 (19.8–78.3)	11.5 (6.5–17.3)	76.0 (20.3–137.0)	39.0 (37.0–84.0)	22.4 (15.1–103.8)	20.0 (8.8–112.2)	168.9 (107.1–287.4)	19.5 (12.0–25.0)	0.078 **				
CRP (mg/dL)	5.6 (3.1–7.2)	1.5 (1.1–3.0)	10.4 (6.3–16.0)	7.6 (4.4–17.5)	10.0 (5.7–16.1)	5.4 (3.8–8.3)	25.8 (17.0–35.4)	15.5 (9.2–17.6)	0.301 **				

* NS = not significant (p > 0.05)

** No difference in change in IL-6 or CRP from Day 1 to Day 3 among groups

IL-6, interleukin 6; CRP, C-reactive protein, IQR, interquartile range, SD, standard deviation